Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CRMD Stock Forecast 2026-2027
$8.32
Current Price
$652.72M
Market Cap
Buy 5
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CRMD Price Targets
+128.4%
To High Target of $19.00
+80.3%
To Median Target of $15.00
+56.3%
To Low Target of $13.00
CRMD Price Momentum
-6.2%
1 Week Change
-4.8%
1 Month Change
-26.8%
1 Year Change
-28.5%
Year-to-Date Change
-44.4%
From 52W High of $14.96
+35.7%
From 52W Low of $6.13
📊 TOP ANALYST CALLS
Did CRMD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if CorMedix is one of their latest high-conviction picks.
Latest CRMD Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, CRMD has a bullish consensus with a median price target of $15.00 (ranging from $13.00 to $19.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $8.32, the median forecast implies a 80.3% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Leonid Timashev at RBC Capital, suggesting a 56.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CRMD Analyst Ratings
5
Buy
0
Hold
0
Sell
CRMD Price Target Range
Low
$13.00
Average
$15.00
High
$19.00
Current: $8.32
Latest CRMD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CRMD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 7, 2026 | RBC Capital | Leonid Timashev | Outperform | Maintains | $13.00 |
| Apr 28, 2026 | RBC Capital | Outperform | Maintains | $N/A | |
| Apr 28, 2026 | Citizens | Market Outperform | Reiterates | $N/A | |
| Apr 28, 2026 | Leerink Partners | Outperform | Maintains | $N/A | |
| Apr 27, 2026 | Needham | Buy | Maintains | $N/A | |
| Apr 27, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Mar 5, 2026 | Needham | Buy | Maintains | $N/A | |
| Feb 11, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Jan 23, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jan 21, 2026 | RBC Capital | Outperform | Maintains | $N/A | |
| Jan 8, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Jan 8, 2026 | Needham | Buy | Maintains | $N/A | |
| Dec 18, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Nov 13, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 12, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Nov 12, 2025 | Needham | Buy | Maintains | $N/A | |
| Oct 21, 2025 | RBC Capital | Outperform | Maintains | $N/A | |
| Oct 20, 2025 | D. Boral Capital | Buy | Upgrade | $N/A | |
| Sep 9, 2025 | JMP Securities | Market Outperform | Reiterates | $N/A | |
| Aug 8, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A |
CorMedix Inc. (CRMD) Competitors
The following stocks are similar to CorMedix based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CorMedix Inc. (CRMD) Financial Data
CorMedix Inc. has a market capitalization of $652.72M with a P/E ratio of 3.8x. The company generates $400.05M in trailing twelve-month revenue with a 45.2% profit margin.
Revenue growth is +226.1% quarter-over-quarter, while maintaining an operating margin of +50.0% and return on equity of +65.6%.
Valuation Metrics
Market Cap
$652.72M
Enterprise Value
$622.05M
P/E Ratio
3.8x
PEG Ratio
0.1x
Price/Sales
1.6x
Growth & Margins
Revenue Growth (YoY)
+226.1%
Gross Margin
+82.5%
Operating Margin
+50.0%
Net Margin
+45.2%
EPS Growth
+87.0%
Financial Health
Cash/Price Ratio
+27.3%
Current Ratio
3.0x
Debt/Equity
33.7x
ROE
+65.6%
ROA
+26.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
CorMedix Inc. (CRMD) Business Model
About CorMedix Inc.
What They Do
Develops biopharmaceutical products for serious health conditions.
Business Model
CorMedix Inc. generates revenue through the commercialization of its therapeutic products, primarily focusing on anti-infective therapies and treatments for hospital settings. Its lead product, DefenCath, is sold to outpatient dialysis organizations, and the company has expanded its portfolio through acquisitions, enhancing its offerings in the acute care and infectious disease markets.
Additional Information
Incorporated in 2006 and based in Berkeley Heights, New Jersey, CorMedix has positioned itself uniquely in the biopharmaceutical industry with its FDA-approved products and a diversified portfolio following the acquisition of Melinta Therapeutics. This expansion allows the company to tap into a broader market beyond dialysis, addressing various hospital-based therapeutic needs.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
64
CEO
Mr. Joseph Todisco MBA
Country
United States
IPO Year
2010
Website
www.cormedix.comCorMedix Inc. (CRMD) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates
Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of -10.96% and -36.76%, respectively, for the quarter ended May 2026. Do the numbers hold clues to what lies ahead for the stock?
Jul 09, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
CorMedix is transitioning from a single-product focus as DefenCath generates revenue, while Rezzayo offers long-term growth potential despite reimbursement challenges.
Why It Matters
CorMedix's transition to a multi-product strategy enhances revenue stability and growth potential, attracting investor interest amid challenges in reimbursement for new products.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
CorMedix expands its portfolio by acquiring Melinta assets and exploring Rezzayo, while aiming for cost synergies amid reimbursement changes affecting long-term earnings.
Why It Matters
CorMedix's expansion into new assets and potential cost synergies may enhance growth prospects, while reimbursement changes could impact long-term profitability, influencing investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
CorMedix reported increased revenue and improved profitability driven by DefenCath. However, reimbursement changes and execution risks may impact future stock performance.
Why It Matters
CorMedix's revenue growth and profitability indicate strong demand, but potential reimbursement changes and execution risks could impact future performance and stock volatility.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
CorMedix Therapeutics (Nasdaq: CRMD) announced that the U.S. Court of Appeals affirmed patent validity for MINOCIN® for Injection, confirming infringement by Nexus Pharmaceuticals.
Why It Matters
The court's affirmation of CorMedix's patent validity boosts MINOCIN®'s market position, potentially increasing revenue and investor confidence in CRMD's future prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
CorMedix (CRMD) is a 'Strong Buy' under $8.35, with a potential 114% upside to a $17.5 fair value. Expected growth post-2027 driven by DefenCath adoption and pipeline developments.
Why It Matters
CorMedix presents a strong investment opportunity with significant upside potential, despite a temporary revenue dip. Growth catalysts and a promising pipeline enhance future value.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
CorMedix (NASDAQ: CRMD) is preparing for potential commercial and regulatory developments, including expanding REZZAYO for fungal infection prophylaxis and enhancing DefenCath utilization amid federal reimbursement changes.
Why It Matters
CorMedix is targeting new markets and regulatory approvals, which could drive revenue growth and improve market position, influencing investor confidence and stock performance.
Source: MarketBeat
Market Sentiment:
Positive
Frequently Asked Questions About CRMD Stock
What is CorMedix Inc.'s (CRMD) stock forecast for 2027?
Based on our analysis of 6 Wall Street analysts, CorMedix Inc. (CRMD) has a median price target of $15.00. The highest price target is $19.00 and the lowest is $13.00.
Is CRMD stock a good investment in 2027?
According to current analyst ratings, CRMD has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.32. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CRMD stock?
Wall Street analysts predict CRMD stock could reach $15.00 in the next 12 months. This represents a 80.3% increase from the current price of $8.32. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is CorMedix Inc.'s business model?
CorMedix Inc. generates revenue through the commercialization of its therapeutic products, primarily focusing on anti-infective therapies and treatments for hospital settings. Its lead product, DefenCath, is sold to outpatient dialysis organizations, and the company has expanded its portfolio through acquisitions, enhancing its offerings in the acute care and infectious disease markets.
What is the highest forecasted price for CRMD CorMedix Inc.?
The highest price target for CRMD is $19.00 from at , which represents a 128.4% increase from the current price of $8.32.
What is the lowest forecasted price for CRMD CorMedix Inc.?
The lowest price target for CRMD is $13.00 from Leonid Timashev at RBC Capital, which represents a 56.3% increase from the current price of $8.32.
What is the overall CRMD consensus from analysts for CorMedix Inc.?
The overall analyst consensus for CRMD is bullish. Out of 6 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $15.00.
How accurate are CRMD stock price projections?
Stock price projections, including those for CorMedix Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2026 7:24 AM UTC